Connecticut AG William Tong, together with a bipartisan coalition of AGs from 23 states and the District of Columbia, filed amicus curiae briefs in two appellate cases before the Third Circuit and the District of Columbia Circuit. In the briefs, the coalition defended the actions of the U.S. Department of Health and Human Services in…

Read More

On April 26, Florida AG Ashley Moody issued an emergency rule adding eight synthetic opioids to Florida’s Schedule I of controlled substances. The drugs, which are categorized as nitazenes, are available on the dark web and throughout the illegal drug market. They are not approved for medical use and , since 2020 alone, have been…

Read More

Kansas AG Derek Schmidt reached a settlement with pharmacy benefit manager Centene Corp. and its subsidiaries (collectively “Centene”) to resolve allegations that it overbilled the state’s Medicaid program. According to the AG’s office, Centene allegedly failed to represent Medicaid’s best interests in negotiations with pharmaceutical suppliers, failed to accurately report discounts it received on certain…

Read More

A bipartisan group of AGs, led by New York AG Letitia James, and the FTC reached a settlement with pharmaceutical company Vyera Pharmaceuticals (formerly known as Turing Pharmaceuticals) and its parent company (collectively “Vyera”) as well as one of its former CEOs, Kevin Mulleady, to resolve allegations that Vyera engaged in anticompetitive and monopolistic practices in violation of the FTC Act, the Sherman Act, and state antitrust laws.

Read More

The Federal Trade Commission (“FTC”) reached a settlement with generic drug companies ANI Pharmaceuticals, Inc. (“ANI”) and Novitium Pharma LLC (“Novitium”), as well as Novitium’s parent company, to resolve allegations that ANI’s acquisition of Novitium would cause future harm to competition in markets for two generic medications in violation of the FTC Act and the…

Read More